Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Cue Biopharma, Inc.

NASDAQ: CUE · Life Sciences · 5 alerts · CIK 1645460

Share price
$14.10Close, Nov 16
Market cap
$102M
Shares outstanding
7.26MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Cue Biopharma, Inc. filings on SEC EDGAR ↗

6:34 PM ET 8-K
Financial Results

Cue Biopharma Financial Results

Cue Biopharma reported third quarter 2026 financial results and highlighted the initiation of first-in-human dosing for CUE-401, its first autoimmune therapeutic candidate. The company also shared positive Phase 2 findings for CUE-221 in chronic spontaneous urticaria (CSU), demonstrating statistically significant hives resolution and potential differentiation from existing therapies like Xolair.

Term
Q3 2026

“We are seeing exciting momentum across our portfolio. We believe CUE-221 has the potential to redefine treatment of IgE-mediated diseases by delivering deeper, more durable disease control and expanding the population of patients who can benefit from anti-IgE therapy.”

Pasha Sarraf, M.D., Ph.D., chairman of the board of Cue Biopharma

“Our goal is to move beyond partial protection toward more complete, sustained protection for patients, including those with high baseline IgE who remain underserved by current therapies. In parallel, we are advancing half-life extension efforts for CUE-221, aimed at further enhancing patient convenience.”

Shao-Lee Lin, M.D., Ph.D., president and chief executive officer of Cue Biopharma
9:40 PM ET Form 4
Insider Selling

Cue Biopharma Chief Legal Compliance Officer Sumita Ray Sells $51.7K of Stock

Sumita Ray, Chief Legal Compliance Officer, sold 1,844 shares of Cue Biopharma, Inc. at $28.05 a share, worth $51.7K in total on Oct 12, 2026. Shares held after the trade: 116,701 (-1.6%).

Value
$51.7K
Shares
1,844
Price
$28.05
Role
Chief Legal Compliance Officer
Holding change
-1.6%
Trade date
Oct 12, 2026
9:38 PM ET Form 4
Insider Selling

Cue Biopharma VP, Prin. Accounting Officer Michael Vincent Meluzio Sells $32.1K of Stock

Michael Vincent Meluzio, VP, Prin. Accounting Officer, sold 1,144 shares of Cue Biopharma, Inc. at $28.05 a share, worth $32.1K in total on Oct 12, 2026. Shares held after the trade: 47,817 (-2.3%).

Value
$32.1K
Shares
1,144
Price
$28.05
Role
VP, Prin. Accounting Officer
Holding change
-2.3%
Trade date
Oct 12, 2026
9:37 PM ET Form 4
Insider Selling

Cue Biopharma CEO Shao-Lee Lin Sells $305K of Stock

Shao-Lee Lin, CEO, sold 11,087 shares of Cue Biopharma, Inc. at $27.50 to $28.05 a share (average $27.55) in 2 transactions, worth $305K in total on Oct 12, 2026. Shares held after the trade: 694,908 (-0.2%).

Value
$305K
Shares
11,087
Average price
$27.55
Role
CEO
Holding change
-0.2%
Trade date
Oct 12, 2026
8:01 AM ET 8-K
Clinical Trial Data

Cue Biopharma Clinical Trial Data

Cue Biopharma announced positive topline results from a Phase 2 clinical trial of CUE-221 in patients with moderate to severe Chronic Spontaneous Urticaria (CSU). The study met its primary endpoint of complete resolution of hives (HSS7=0) at all dose levels with high statistical significance, demonstrating superiority over placebo and showing a favorable safety profile. The company plans to advance the candidate into a Phase 2b/3 registration-enabling study based on these results.

Counterparty
Genesis Life Sciences
Term
36 weeks

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.